Gunderson Dettmer Advises Underwriters on Arcus Biosciences, Inc. Follow-on Offering

June 2, 2020Client News

Gunderson Dettmer advised the underwriters on Arcus Biosciences’ follow-on public offering of 11,000,000 shares at $27.50 per share with aggregate gross proceeds of approximately $302.5 million.

Citigroup, SVB Leerink and Evercore ISI acted as joint book running managers for the offering. Capital markets partner Jeff Vetter and corporate partner Marcia Hatch, along with associates Colin Conklin, Anjuli Schlievert and Jessica Jeong, led the team advising the underwriters.

Arcus Biosciences, which is traded on the NYSE under the ticker “RCUS,” is an oncology-focused biopharmaceutical company that utilizes cross disciplinary expertise.